Korea S.E.
06:00:00 2024-07-11 pm EDT
5-day change
1st Jan Change
7,060
KRW
+1.00%
+1.29%
+24.73%
OTOM Co., Ltd. announced that it has received KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
OTOM Co., Ltd. announced that it has received KRW 2 billion in round of funding on March 6, 2024. The transaction included the participation from new investor DongKoo Bio & Pharma Co., Ltd.
Qurient Co., Ltd. announced that it has received KRW 13.499996307 billion in funding from DongKoo Bio & Pharma Co., Ltd.
May. 16
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
May. 02
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
May. 02
CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on November 2, 2023, has expired with 321,701 shares, representing 1.17% for KRW 1,998.73 million.
May. 01
CI
Qurient Co., Ltd. announced that it expects to receive KRW 13.499998256 billion in funding from DongKoo Bio & Pharma Co., Ltd. and another investor
Apr. 11
CI
OTOM Co., Ltd. announced that it has received KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
Mar. 05
CI
HDT Co., Ltd announced that it expects to receive KRW 2 billion in funding from DongKoo Bio & Pharma Co., Ltd.
Feb. 27
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on November 2, 2023.
Feb. 02
CI
DongKoo Bio & Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
Nov. 01
CI
DongKoo Bio&Pharma Co., Ltd. authorizes a Buyback Plan.
Nov. 01
CI
DongKoo Bio & Pharma Co., Ltd.(KOSDAQ:A006620) dropped from S&P Global BMI Index
23-09-18
CI
DongKoo Bio & Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-03-20
CI
HLB Pharmaceutical Co., Ltd announced that it has received KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
22-08-09
CI
HLB Pharmaceutical Co., Ltd announced that it expects to receive KRW 20 billion in funding from JW Holdings Corporation, Prime Life & Health Co., Ltd., DongKoo Bio & Pharma Co., Ltd.
22-08-08
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
22-07-26
CI
Tranche Update on DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
22-07-26
CI
DongKoo Bio & Pharma Co., Ltd.'s Equity Buyback announced on January 28, 2022, has expired with 416,327 shares, representing 1.49% for KRW 2,995.1 million.
22-07-26
CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on January 28, 2022.
22-04-27
CI
Tranche Update on DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback Plan announced on October 14, 2021.
22-04-12
CI
DongKoo Bio&Pharma Co., Ltd.'s Equity Buyback announced on October 14, 2021, has expired with 251,612 shares, representing 0.89% for KRW 1,997.79 million.
22-04-12
CI
DongKoo Bio&Pharma Co., Ltd. announces an Equity Buyback for KRW 3,000 million worth of its shares.
22-01-27
CI
DongKoo Bio&Pharma Co., Ltd. authorizes a Buyback Plan.
22-01-27
CI
Valted Seq, Inc. announced that it has received $12.99 million in funding from DongKoo Bio&Pharma Co., Ltd., Loftyrock Investment Co., Ltd., OV Principal Investments, LLC and other investors
22-01-26
CI
Valted Seq, Inc. announced that it has received $10.5 million in funding from DongKoo Bio&Pharma Co., Ltd. and other investors
21-11-01
CI
DongKoo Bio&Pharma Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
21-10-13
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Dongkoo Bio&Pharma Co.,Ltd. is a Korea-based company mainly engaged in the production and sale of pharmaceuticals. The major products include antihistamines, topical steroids, therapeutic agents for prostatitis, treatments for benign prostatic hyperplasia, atherosclerotic agents, and antibiotics, among others. The Company is involved in contract manufacturing organization business. It manufactures and sells therapeutic for osteoporosis, antiviral agents, erectile dysfunction treatments, hepatic disease agents; painkillers; gum treatments. In addition, the Company is engaged in the manufacturing and sale of medical devices and cosmetics. The Company distributes its products within the domestic market and to overseas markets, including America and Europe.
More about the company
1st Jan change
Capi.
+24.73% 140M +62.66% 854B +40.42% 636B -4.37% 361B +17.16% 324B +9.87% 301B +15.66% 247B +17.90% 228B +14.86% 177B +0.45% 164B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
DONGKOO BIO & PHARMA CO., LTD. 
